Primary Outcome Measures Objective Response Rate (ORR) defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. Up to 36 months Secondary Outcome Measures Progression Free Survival (PFS) defined[…]
Clinical Trials
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Primary Objective The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy. Secondary Objective The secondary objectives are to determine[…]
Studying the Clinical Trial Experiences of Patients With Mesothelioma
Primary Outcome Measures Rate of patients who decide to enroll in a mesothelioma medical study. [ Time Frame: 3 months ] Number of mesothelioma patients who remain in clinical trial until completion. [ Time Frame: 12 months ] Inclusion Criteria Must have a medical diagnosis of mesothelioma that has been confirmed by a physician. Aged ≥ 18 years[…]
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Primary Outcome Measures Phase 1 (Dose Escalation): Incidence of adverse events [ Time Frame: From CTX131 infusion up to 28 days post-infusion ] Defined as dose-limiting toxicities Phase 2 (Cohort Expansion): Objective response rate (ORR) [ Time Frame: From CTX131 infusion up to 60 months post-infusion ] ORR based on Independent Review Committee (IRC) assessment, defined as the[…]
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)
Primary Outcome Measures Proportion of patients that experienced (S)AEs possibly, probably or definitely related to pemetrexed and/or cisplatin/carboplatin and/or atezolizumab and/or WT1/DC vaccination [ Time Frame: through study completion, an average of 2 years ] The relationship of an AE to the investigational agents will be determined by the Investigator as either related or[…]
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Primary Outcome Measures Phase 1 Maximum Tolerated Dose [ Time Frame: 28 days ] To determine the maximum tolerated dose (MTD) of TNG462 Phase 1 Dosing Schedule [ Time Frame: 28 days ] To determine the dosing schedule of TNG462 Phase 2 Anti-neoplastic Activity [ Time Frame: 16 weeks ] To assess anti-neoplastic activity of TNG462 in patients with MTAP-deleted advanced solid[…]
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Primary Outcome Measures Number of patients tolerating dose levels (maximum tolerated dose; MTD) in each of the combinations [ Time Frame: Assessed from baseline to 30 days after last dose of study drug ] MTD of NUC-3373 in each of the combinations in each patient Number of patients reporting treatment-emergent adverse events (TEAEs) in[…]
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Primary Outcome Measures Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year. ] Inclusion Criteria Signed consent to long-term follow-up on protocol PA17-0483 Patients with advanced clear cell renal cell carcinoma,[…]
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma (HIT-Meso)
Primary Outcome Measures Progression free survival [ Time Frame: From randomisation up to 2 years of follow up ] Defined as the time from randomisation to the date of disease progression Overall survival [ Time Frame: From randomisation up to 2 years of follow up ] defined as the time from randomisation to the date of death from[…]
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Primary Outcome Measures Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD) [ Time Frame: 28 days during 1st cycle ] Determine the MTD and/or MAD of anti GP88 monoclonal antibody (AG-01) in subjects with advanced/refractory solid tumor malignancies for which no effective therapies exist. Antitumor Activity of AG-01 by Overall Response Rate (ORR)[…]
